Delayed hepatocarcinogenesis through antiangiogenic intervention in the nuclear factor-kappa B activation pathway in rats

Hepatobiliary and Pancreatic Diseases International

Volumn 9, Issue 2, 2010, Pages 169-174

  Dong, Zhi Zhen ^a   Yao, Deng Fu ^b   Wu, Wei ^b   Yao, Min ^b   Yu, Hong Bo ^c   Shen, Jun Jun ^b   Qiu, Li Wei ^b   Yao, Ning Hua ^b   Sai, Wen Li ^b   Yang, Jun Ling ^b  

^a NANTONG MEDICAL COLLEGE   (China)

^b NANTONG UNIVERSITY   (China)

^c Nantong Cancer Hospital   (China)

Author keywords

Dynamic expression; Hepatocellular carcinoma; Intervention; Nuclear factor kappa B; Vascular endothelial growth factor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; N (2 FLUORENYL)ACETAMIDE; THALIDOMIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951873502     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 2009;1155:206-221.
2. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007;13:74-81. (Pubitemid 46165464)
3. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346. (Pubitemid 35154440)
4. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006;210:171-186.
5. Arsura M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005;229:157-169.
6. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436. (Pubitemid 44050137)
7. Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, Ng IO. Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 2004;10:4140-4149.
8. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009;50:490-499.
9. Vainer GW, Pikarsky E, Ben-Neriah Y. Contradictory functions of NF-kappaB in liver physiology and cancer. Cancer Lett 2008;267:182-188.
10. O'Neil BH, Bůzkov́P, Farrah H, Kashatus D, Sanoff H, Goldberg RM, et al. Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology 2007; 72:97-104. (Pubitemid 350249136)
11. Guo K, Kang NX, Li Y, Sun L, Gan L, Cui FJ, et al. Regulation of HSP27 on NF-kappaB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis. BMC Cancer 2009;9:100.
12. Cheng JC, Chou CH, Kuo ML, Hsieh CY. Radiationenhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006;25:7009-7018. (Pubitemid 44722069)
13. Park SG, Lee T, Kang HY, Park K, Cho KH, Jung G. The influence of the signal dynamics of activated form of IKK on NF-kappaB and anti-apoptotic gene expressions: a systems biology approach. FEBS Lett 2006;580:822-830. (Pubitemid 43152301)
14. Auyeung KK, Law PC, Ko JK. Astragalus saponins induce apoptosis via an ERK-independent NF-kappaB signaling pathway in the human hepatocellular HepG2 cell line. Int J Mol Med 2009;23:189-196.
15. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007;13: 1076-1082. (Pubitemid 46424045)
16. Yao DF, Jiang DR, Wu XH. Experimental study on value of carcino-embryonic gama-glutamyl transferase isoenzymes for monitoring carcinogenesis of hepatocytes. Zhonghua Gan Zang Bing Za Zhi 2000;8:30-32.
17. Yao DF, Wu XH, Zhu Y, Shi GS, Dong ZZ, Yao DB, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005;4:220-226. (Pubitemid 40790169)
18. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008;14:5124-5130.
19. Chung C, Park SG, Park YM, Joh JW, Jung G. Interferongamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappaB activation. Cancer Sci 2007;98:1758-1766. (Pubitemid 47487913)
20. Sato Y, Kato J, Takimoto R, Takada K, Kawano Y, Miyanishi K, et al. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut 2006;55:1801-1808. (Pubitemid 44893582)
21. Lee SH, Park SG, Lim SO, Jung G. The hepatitis B virus X protein up-regulates lymphotoxin alpha expression in hepatocytes. Biochim Biophys Acta 2005;1741:75-84. (Pubitemid 40824992)
22. Lee TH, Tai DI, Cheng CJ, Sun CS, Lin CY, Sheu MJ, et al. Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics. J Biomed Sci 2006;13: 27-39.
23. Wang J, Tokoro T, Higa S, Kitajima I. Anti-inflammatory effect of pitavastatin on NF-kappaB activated by TNF-alpha in hepatocellular carcinoma cells. Biol Pharm Bull 2006;29: 634-639.
24. Guo LL, Xiao S, Guo Y. Activation of transcription factors NF-kappaB and AP-1 and their relations with apoptosis associated-proteins in hepatocellular carcinoma. World J Gastroenterol 2005;11:3860-3865. (Pubitemid 41025238)
25. Pinter M, Wichlas M, Schmid K, Plank C, Müler C, Wrba F, et al. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur J Gastroenterol Hepatol 2008;20:1012-1019.
26. Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2008;14:6437-6441.
27. Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via deregulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 2008;33:287-295.
28. Calvisi DF, Pascale RM, Feo F. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials 2007;2:217-236. (Pubitemid 47558825)
29. Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, Rocken C, et al. Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther 2006;17:280-290.
30. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 2006;45:355-361.
31. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13:738747.
32. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, et al. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett 2009;278:145-155.